StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.33 | $7.36 | +0.41% | 0.9M |
| 05-12 | $7.28 | $7.45 | +2.34% | 1.4M |
| 05-13 | $7.45 | $7.49 | +0.54% | 1.0M |
| 05-14 | $7.48 | $7.42 | -0.80% | 0.4M |
| 05-15 | $7.19 | $6.90 | -4.03% | 1.4M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
| Metric | Q1 2014 2014-02-28 | Q4 2013 2013-11-30 | Annual 2013 2013-08-31 | Q2 2013 2013-05-31 |
|---|---|---|---|---|
Revenue | $15.60K | $14.92K | $13.07K | $13.07K |
Operating Income | $-74.66K | $-71.53K | $-57.16K | $-44.79K |
Net Income | $-74.66K | $-71.53K | $-50.89K | $-44.79K |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $10.00K | $12.30K | $20.01K | $4.73K |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $2.63K | $6.17K | $15.29K | $664.00 |
Free Cash Flow OCF − CapEx | $-40.87K | $-37.33K | $-28.21K | $-22.84K |
Shares Outstanding | Not available | Not available | Not available | Not available |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.